Fintel reports that on January 21, 2026, Chardan Capital initiated coverage of Alumis (NasdaqGS:ALMS) with a Buy recommendation. Analyst Price Forecast Suggests 39.23% Upside As of January 14, 2026, ...

The average one-year price target for Alumis (NasdaqGS:ALMS) has been revised to $36.28 / share. This is an increase of 79.14 ...

The first purchase involved 117,647 shares, while the second purchase consisted of 294,117 shares.

Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this ...

Alan Colowick, a director at $ALMS, bought 16,104 shares of the company on 04-01-2025 for an estimated $112,309. This trade was reported by Quiver Quantitative using ...

Alumis Inc. (NASDAQ: ALMS) stock is trading higher on Tuesday, with a session volume of 4.33 million compared to the average volume of 1.02 million as per data from Benzinga Pro. Alumis on Tuesday ...

Alumis (ALMS) has drawn fresh attention after reporting positive topline Phase 3 ONWARD results for envudeucitinib in moderate to severe plaque psoriasis. All primary and secondary endpoints were met, ...

On Monday, Morgan Stanley resumed its coverage of Alumis Inc. (NASDAQ:ALMS) with an Overweight rating and a $23 price target after the company’s recent merger with Acelyrin and its Q1 2025 earnings ...

Foresite Capital Fund VI, L.P. holds 4,247,670 shares, Labs Co-Invest V, LLC holds 194,459 shares, Foresite Labs Fund I, L.P. holds 1,960,337 shares, and Foresite Labs Affiliates 2021, LLC holds 1,176 ...

None ...